Clinical Trial: A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge (China)

Posted On: 2026-08-18

China, Aug. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130178

Registration Time: 2026/08/17

Type: Interventional study

Primary Sponsor: hunan cancer hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=329106

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A clinical study on the maintenance treatment of platinum-sensitive recurrent ovarian cancer patients who have previously received PARPi, combined with epalrestat and torvelinabucelumab rechallenge (China)